---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-005680"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2024-09-12T23:59:59+00:00"
generated_at: "2026-05-31T05:15:37.280168+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab invests $450K in color paste production; signs MOU with Shenzhen Rongguang Health

## Summary
- Chemrex invests RM 2M (~$450K) to produce fine-quality color paste for composite industrial customers; operations start Sept 2024.
- In-house production expected to increase profit margins, improve quality control, and enable competitive pricing.
- Company plans additional production facilities in the Middle East and Vietnam; bulk purchasing synergies.
- MOU with Shenzhen Rongguang Health Group aims to expand cancer screening, precision medicine, and preventative healthcare in Asia.
- MRNA Scientific subsidiary will lead cancer screening expansion with advanced genomic testing across Southeast Asia and China.

## SEC filing metadata
- accession: 0001477932-24-005680
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2024-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793224005680/0001477932-24-005680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793224005680/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-005680
- JSON: https://secwatch.observer/filing/0001477932-24-005680.json
- Plain text: https://secwatch.observer/filing/0001477932-24-005680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.